Concord Biotech Q1FY27 Revenue Grows 26% to ₹257.5 Crore; Exports Surge 46%
Concord Biotech reported Q1FY27 consolidated revenue of ₹257.5 crore, a 26% year-on-year increase. Exports surged 46% to ₹121.7 crore. EBITDA grew 34% to ₹82.4 crore, and PAT rose 31% to ₹57.7 crore. The company received USFDA approval for Mycophenolate Mofetil & Tofacitinib Tablets ANDAs and a Silver medal from EcoVadis.
The announcement details significant financial growth, key regulatory approvals (USFDA), and positive international recognition (EcoVadis), all of which are material factors impacting investor confidence and the company's market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with significant export growth. Positive developments include USFDA approvals and a sustainability rating, indicating a healthy business outlook.
Concord Biotech Limited has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company reported a strong revenue growth of 26% year-on-year, reaching ₹257.5 crore in Q1FY27. This growth was driven by broad-based performance across all product categories and geographies, with export revenue increasing by an impressive 46% year-on-year.
The company witnessed increased business from existing customers, leading to a higher wallet share, and also expanded its customer base with new product additions. The robust product pipeline targets the launch of 2-3 products annually. Key highlights include USFDA approvals for ANDAs of Mycophenolate Mofetil & Tofacitinib Tablets.
Regulatory advancements include successful inspections by ANVISA (Brazil), Pharmacy and Poisons Board (Kenya), and National Drug Authority (Uganda) at its manufacturing facilities. Concord Biotech also received a Silver medal from EcoVadis, placing it among the top 15% of companies assessed globally for sustainability.
Consolidated financial highlights for Q1FY27 show Revenue at ₹257.5 crore (up 26% YoY), EBITDA at ₹82.4 crore (up 34% YoY), and PAT at ₹57.7 crore (up 31% YoY). Gross Profit Margin improved to 78.9% and EBITDA Margin to 32.0%. The company also commenced commercial operations and sales at Stellon Biotech and is seeing advanced customer engagement for its injectable products.
Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer, expressed satisfaction with the performance, emphasizing the company's strong capabilities in delivering globally compliant products and reinforcing its leadership in niche fermentation-based molecules. He highlighted the successful regulatory inspections and expressed confidence in outperforming industry growth.
What to do with a filing like this
Concord Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Concord Biotech Limited. Read the original for the full detail.